Avelumab in First Line Maintenance in Advanced Urothelial Carcinoma (aUC) in Elderly Patients: Efficacy, Tolerability, and Quality of Life in Real Life Setting

Avelumab in First Line Maintenance in Advanced Urothelial Carcinoma (aUC) in Elderly Patients: Efficacy, Tolerability, and Quality of Life in Real Life Setting

(1) Background Immune checkpoint inhibitors (ICIs) have recently become an important therapeutic option for patients with advanced urothelial carcinoma (aUC). Avelumab is an anti-PD-L1 (programmed cell death ligand 1) antibody that restores antitumor T-cell immune function by blocking the binding of...

Full description

Saved in:
Bibliographic Details
Main Authors: Rossella De Luca, Pasquale Vitale, Alessio Pepe, Roberta Spedaliere, Alchiede Simonato, Raffaele Addeo, Giuseppe Cicero
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Scientia Pharmaceutica
Subjects:
Avelumab
immunotherapy
advanced urothelial carcinoma
progression free survival
quality of life
Online Access:https://www.mdpi.com/2218-0532/92/4/62
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items